Again, there are no big changes for stock classification. Picked biotech stocks are categorized into several groups: I) short-term investment (this will include biotech scams that can be pumped in nearest future); II) biotech gems that have strong science basis and pps below $15, potential buyouts targets for Big Pharmas; III) big cap biotechs for long-term investment (3 and more years)I.
1)
ORMP (Phase 3 start for oral insulin pills can drive pps of this scam to $15 and higher)
2)
ATHE (new name for old scam biotech PRAN)
3) SRNE
4) SAVA
II.
1)
CARA is still BUY, good phase 3 results for IV pain-killer can induce +50-60% spike)
2) ZIOP (buyout target for Big Pharma in 2021, possible upside +200%)
3) MBII (not drugs biotech, they provide bio-based pest management and plant health products. Good enter price and huge potential)
4) AGRX
5) TRVN
6) CFRX
7) LPTX
8) SLNO
9) MRNS
10) CLVS
11)
III.
1) NVO
2) ACAD
3) ALKS
4) EXEL
5) GBT
6) IONS
7) SGEN
8) RARE
9) AIMT
10) ABBV
11) NVCR
12) PTCT
13) KPTI
14) TGTX
to be continued...
I will avoid in 2020:
1) BLUE
4) PGEN (still "empty" biotech - just changed name from XON, just promises and speculations)
5) XOMA
6) EDIT